IBS-D — Deal Benchmarks & Valuation
Market Analysis
IBS-D is one of the most actively transacted indications in gastroenterology licensing. Phase 2 deals for ibs-d carry a median total deal value of $1.9B, with upfront payments ranging from $203M to $551M. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones.
Milestone structures for ibs-d deals allocate $327M to development milestones, $390M to regulatory milestones, and $841M to commercial milestones. Royalty rates range from 6.9% to 12.9% at the base tier, with tiered escalation reaching 10.9%-16.9% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for ibs-d licensing?
What royalty rates are standard for ibs-d deals?
How are ibs-d deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.